Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
0.6960
-0.0341 (-4.67%)
At close: Jun 5, 2026, 4:00 PM EDT
0.6971
+0.0011 (0.16%)
After-hours: Jun 5, 2026, 6:40 PM EDT
Galmed Pharmaceuticals Employees
As of December 31, 2025, Galmed Pharmaceuticals had 6 total employees, including 3 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,718,167
Market Cap
4.58M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 6 | 0 | - | 3 | 3 |
| Dec 31, 2024 | 6 | -2 | -25.00% | 3 | 3 |
| Dec 31, 2023 | 8 | -2 | -20.00% | 3 | 5 |
| Dec 31, 2022 | 10 | -14 | -58.33% | 4 | 6 |
| Dec 31, 2021 | 24 | 0 | - | 19 | 5 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 39 |
| GeoVax Labs | 19 |
| Virax Biolabs Group | 19 |
| Soligenix | 14 |
| TransCode Therapeutics | 12 |
| Dermata Therapeutics | 9 |
| Alzamend Neuro | 6 |
| Mustang Bio | 4 |
GLMD News
- 5 days ago - Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis - TheFly
- 5 days ago - Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis - TheFly
- 5 days ago - Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis - PRNewsWire
- 24 days ago - Galmed reports results from first-in-man PK study of Aramchol Meglumine - TheFly
- 24 days ago - Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg - PRNewsWire
- 4 weeks ago - Galmed partnering with Tissue Dynamics to develop cardiac fibrosis platform - TheFly
- 4 weeks ago - Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics - PRNewsWire
- 7 weeks ago - Galmed announces research agreement with Ramot at Tel Aviv University - TheFly